SUSCA, SARA

SUSCA, SARA  

SCIENZE MEDICHE  

Mostra records
Risultati 1 - 19 di 19 (tempo di esecuzione: 0.026 secondi).
Titolo Data di pubblicazione Autore(i) File
"Superresponders" at biologic treatment for psoriasis: A comparative study among IL17 and IL23 inhibitors 2022 Mastorino, Luca; Susca, Sara; Cariti, Caterina; Verrone, Anna; Stroppiana, Elena; Ortoncelli, Michela; Dapavo, Paolo; Ribero, Simone; Quaglino, Pietro
A new suture technique for flap closure in dermatologic surgery 2022 Parietti, Michele; Susca, Sara; Ribero, Simone
Anti-IL23 in inflammatory bowel disease patients with dermatological indication: The shared gastroenterological-dermatological clinic experience 2024 Ribaldone D.G.; Palumbo A.; Susca S.; Merli M.; Dapavo P.; Vernero M.
Brodalumab efficacy in bio-naïve psoriasis patients: real-life experience of 202 subjects up to 48 weeks 2022 Mastorino, Luca; Cariti, C; Susca, S; Boskovic, S; Aquino, C; Ortoncelli, M; Stroppiana, E; Verrone, A; Dapavo, P; Quaglino, P; Ribero, Simone
Clinical characteristics and response to biological therapies for inverse psoriasis: a real‐life comparison between the therapeutic effects of anti‐IL‐23 and anti‐IL‐17 agents 2024 Mastorino, Luca; Dapavo, Paolo; Macagno, Nicole; Ortoncelli, Michela; Verrone, Anna; Stroppiana, Elena; Cariti, Caterina; Susca, Sara; Siliquini, Niccolò; di Corteranzo, Isotta Giunipero; Quaglino, Pietro; Ribero, Simone
Comparison between brodalumab, secukinumab and ixekizumab effectiveness and drug survival: A real-life experience on 638 patients with psoriasis 2023 Mastorino, Luca; Cariti, Caterina; Susca, Sara; Siliquini, Niccolò; Verrone, Anna; Stroppiana, Elena; Ortoncelli, Michela; Dapavo, Paolo; Quaglino, Pietro; Ribero, Simone
Comparison of Secukinumab and Ixekizumab in psoriasis: a real-life cohort study on the efficacy and drug survival of 445 patients 2022 Cariti, C; Dapavo, P; Mastorino, L; Ortoncelli, M; Siliquini, N; Merli, M; Avallone, G; Giordano, S; Fabrizio, R; Susca, S; Verrone, A; Stroppiana, E; Quaglino, P; Ribero, S
Drug survival and clinical effectiveness of secukinumab, ixekizumab, brodalumab, guselkumab, risankizumab, tildrakizumab for psoriasis treatment 2023 Mastorino, Luca; Dapavo, Paolo; Susca, Sara; Cariti, Caterina; Siliquini, Niccolò; Verrone, Anna; Stroppiana, Elena; Ortoncelli, Michela; Quaglino, Pietro; Ribero, Simone
Drug survival and efficacy of anti-interleukin 23 biologics in psoriasis: a comparative study on different agents 2023 Roccuzzo, Gabriele; Mastorino, Luca; Susca, Sara; Cariti, Caterina; Passerini, Stefania G; Sciamarrelli, Nadia; Borriello, Silvia; Macagno, Nicole; Sliquini, Niccolò; Avallone, Gianluca; Verrone, Anna; Stroppiana, Elena; Quaglino, Pietro; Ortoncelli, Michela; Dapavo, Paolo; Ribero, Simone
Drug survival und klinische Wirksamkeit von Secukinumab, Ixekizumab, Brodalumab, Guselkumab, Risankizumab und Tildrakizumab in der Behandlung der Psoriasis: Drug survival and clinical effectiveness of secukinumab, ixekizumab, brodalumab, guselkumab, risankizumab, tildrakizumab for psoriasis treatment 2024 Mastorino, Luca; Dapavo, Paolo; Susca, Sara; Cariti, Caterina; Siliquini, Niccolò; Verrone, Anna; Stroppiana, Elena; Ortoncelli, Michela; Quaglino, Pietro; Ribero, Simone
Drug Survival, Safety, and Effectiveness of Secukinumab for up to 5 Years in Patients with Psoriasis and Psoriatic Arthritis: A Long-Term Real-Life Experience 2024 Mastorino, Luca; Dapavo, Paolo; Cariti, Caterina; Susca, Sara; Siliquini, Niccolò; Ortoncelli, Michela; Stroppiana, Elena; Verrone, Anna; Giunipero di Corteranzo, Isotta; Leo, Francesco; Quaglino, Pietro; Ribero, Simone
Dual-targeted therapy with apremilast and vedolizumab in pyoderma gangrenosum associated with Crohn’s disease 2020 Vernero M.; Ribaldone D.G.; Cariti C.; Ribero S.; Susca S.; Astegiano M.; Dapavo P.
Effectiveness of Brodalumab on Scalp, Palmoplantar, and Genital Psoriasis: A Descriptive Pilot Study 2023 Mastorino L.; Celoria V.; Macagno N.; Cariti C.; Susca S.; Siliquini N.; Ortoncelli M.; Stroppiana E.; Verrone A.; Burzi L.; Quaglino P.; Ribero S.; Dapavo P.
Efficacy of anti-IL-23 and anti-IL-17 after adalimumab failure in psoriatic patients 2023 Mastorino, L; Susca, S; Cariti, C; Sliquini, N; Verrone, A; Stroppiana, E; Ortoncelli, M; Dapavo, P; Ribero, S; Quaglino, P
Mask-related acne flares during the COVID era 2022 Cariti, Caterina; Cavallo, Francesco; Panzone, Michele; Susca, Sara; Quaglino, Pietro; Ribero, Simone
Oral doxycycline in HIV-related synchronous malignant syphilis and condyloma lata 2022 Avallone, Gianluca; Cavallo, Francesco; Susca, Sara; Mastorino, Luca; Trunfio, Mattia; Bonora, Stefano; Rugge, Walter; Calleri, Guido; Conti, Luca; Senetta, Rebecca; Marra, Elena; Fierro, Maria T; Quaglino, Pietro; Ribero, Simone
Risankizumab shows faster response in bio naïve than in bio-experienced psoriatic patients 2022 Mastorino, L; Castelli, F; Stroppiana, E; Verrone, A; Ortoncelli, M; Susca, S; Boskovic, S; Passerini, S G; Macagno, N; Cariti, C; Licciardello, M; Solaroli, C; Pertusi, G; Aragone, M G; Baggini, G; Addese, C; Leporati, C; Peila, R; Giura, M T; Rossotto, G; Pella, P; Mocci, L; Merlo, G; Tiberio, R; Graziola, F; Quaglino, P; Dapavo, P; Ribero, S
Risankizumab shows high efficacy and maintenance in improvement of response until week 52 2022 Mastorino L.; Susca S.; Megna M.; Siliquini N.; Quaglino P.; Ortoncelli M.; Avallone G.; Rubatto M.; Fabbrocini G.; Dapavo P.; Ribero S.
Tildrakizumab in real-life shows good efficacy in moderate-to-severe psoriasis regardless of previous use of biologic drugs and joint involvement 2022 Mastorino, Luca; Cariti, Caterina; Susca, Sara; Sciamarrelli, Nadia; Borriello, Silvia; Ortoncelli, Michela; Stroppiana, Elena; Verrone, Anna; Dapavo, Paolo; Quaglino, Pietro; Ribero, Simone